Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM-SPIRE for house dust mite-induced rhinoconjunctivitis
2014-001662-94Phase 2Completed
- Sponsor
- NIOX Group
- Start
- Jul 2014
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HDM-SPIRE in allergic rhinoconjunctivitis (ARC) and perennial rhinitis (3 arms), sponsored by NIOX Group. Primary endpoint: Mean Combined Score during PAC3 period. Started Jul 2014; status: completed.
02
Drugs
HDM-SPIRE
03
Conditions
allergic rhinoconjunctivitis (ARC)perennial rhinitis
Beyond the preview
Go deeper on 2014-001662-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001662-94.